Abstract
AbstractBackground:This research aimed to evaluate the clinical treatment outcomes of T2N0M0 glottic laryngeal squamous cell carcinoma (LSCC) patients who underwent laryngectomy.Methods:Retrospectively review of 541 T2N0M0 glottic LSCC patients.Results:5-year cancer-specific survival (CSS) rate was 89.6%, and the overall survival (OS) rate was 88.5%. No statistically difference was found between the patients who have undergone total laryngectomy (5-year DFS = 80.7%, and the CSS = 86.7%) and those who have had partial laryngectomy (the 5-year DFS = 84.6%, and CSS = 90.5%). There was no difference in the CSS and DFS rates between patients with negative margins and those with positive margins following postoperative radiotherapy (PORT) ± chemotherapy (the CSS: 90.5% vs.79.9%, P = 0.335 and 5-year DFS: 84.2% vs. 77.8%, P = 0.289). Patients who underwent vertical partial laryngectomy (VPL) had better survival (5-year OS was 91.9%, and the CSS was 92.8%) than those who underwent cricohyoidoepiglottopexy (CHEP) or cricohyoidopexy (CHP) (the 5-year OS = 83.8%, P = 0.022 and CSS = 84.9%, P = 0.038).Conclusion:Surgery remains the gold standard for treating T2N0M0 glottic LSCC patients because it can achieve satisfactory oncological outcomes. Regarding the systemic conditions, the effect of partial laryngectomy is similar to that of total laryngectomy. Moreover, partial laryngectomy preserves the function of the larynx. VPL may be superior to CHP/CHEP, depending upon the invasiveness of the tumor.
Publisher
Research Square Platform LLC
Reference33 articles.
1. Cancer statistics, 2013;Siegel R;CA: a cancer journal for clinicians,2013
2. Management and outcome differences in supraglottic cancer between Ontario, Canada, and the Surveillance, Epidemiology, and End Results areas of the United States;Groome PA;Journal of clinical oncology: official journal of the American Society of Clinical Oncology,2003
3. Management of T1-T2 glottic carcinomas;Mendenhall WM;Cancer,2004
4. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008;Ferlay J;International journal of cancer,2010
5. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology;Pfister DG;Journal of the National Comprehensive Cancer Network: JNCCN,2020